RARE DISEASERESEARCH ATLAS

ORPHA:36386

Hereditary sensory and autonomic neuropathy type 1

high confidenceDisorder

Also known as: Hereditary sensory and autonomic neuropathy type I · HSAN1

Publications

450

74th percentile

Trials

2

Interventional, condition-specific

Researchers

1,216

Distinct authors in sample

Gene link

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare slowly neurological disorder characterized by prominent predominantly distal sensory loss, autonomic disturbances in some patients, inheritance, and juvenile or adulthood disease onset.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

Hereditary Sensory Neuropathy Type I · hereditary sensory and autonomic neuropathy type I

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    450 matched papers (279 in last 10 years) Source

  3. Phenotype characterisedPresent

    147 HPO annotations (e.g. Cataract; Hyporeflexia; Skeletal muscle atrophy) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    2 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

147

Associated phenotypes · MONDO:0018213

  • Cataract
  • Hyporeflexia
  • Skeletal muscle atrophy
  • Hand tremor
  • Decreased number of large peripheral myelinated nerve fibers

Showing 5 of 147 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

1

Drugs / clinical candidates · MONDO_0018213

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

450

450 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

450 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

279 in the last 10 years · high confidence · 74th percentile (publications denominator)

Phrase hits: 450 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,216

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Hornemann T31 papers · 2026

    Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland. Electronic address: thorsten.hornemann@usz.ch.

    Papers in Europe PMC
  2. 02
    Dunn TM13 papers · 2026

    Department of Biochemistry and Molecular Biology, Uniformed Services University, Bethesda, MD 20814-4799.

    Papers in Europe PMC
  3. 03
    Lone MA11 papers · 2026

    Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland.

    Papers in Europe PMC
  4. 04
    von Eckardstein A10 papers · 2025

    Institute for Clinical Chemistry, University Hospital Zurich, Zurich 8091, Switzerland.

    Papers in Europe PMC
  5. 05
    Gable K9 papers · 2026

    Department of Biochemistry, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20184-4799, USA.

    Papers in Europe PMC
  6. 06
    Metallo CM9 papers · 2026

    Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.

    Papers in Europe PMC
  7. 07
    Reilly MM9 papers · 2026

    Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.

    Papers in Europe PMC
  8. 08
    Othman A8 papers · 2019

    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck D-23562, Germany.

    Papers in Europe PMC
  9. 09
    Penno A8 papers · 2021

    Institute for Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.

    Papers in Europe PMC
  10. 10
    Mohassel P7 papers · 2024

    Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Dr., Bethesda, MD 20892, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

2

interventional trials for this specific condition

2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 1 trial are registered for hereditary sensory and autonomic neuropathy, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).

high confidence · 84.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

2 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Broader category: hereditary sensory and autonomic neuropathy

1

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Hereditary sensory and autonomic neuropathy type 1 — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Hereditary sensory and autonomic neuropathy type 1" OR "Hereditary sensory and autonomic neuropathy type I" OR "HSAN1" OR "Hereditary Sensory Neuropathy Type I"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Hereditary sensory and autonomic neuropathy type 1" OR "Hereditary sensory and autonomic neuropathy type I" OR "HSAN1" OR "Hereditary Sensory Neuropathy Type I"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"hereditary sensory and autonomic neuropathy"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T23:53:38.484Z